Prime Medicine, Inc. (PRME) Stock Analysis — Probabli.AI
AI-powered analysis for PRME (Prime Medicine, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $3.43 · Market cap: $619.3M · AI outlook: Bullish
Prime Medicine, Inc. is positioned as an innovative leader in the gene editing and gene therapy field with high potential upside due to its groundbreaking technology and strong strategic initiatives. However, risks related to clinical results, regulatory hurdles, and market acceptance should not be overlooked. The positive analyst consensus coupled with recent funding rounds and partnerships…
Probabilistic 1-Year Outlook
- Bull 60% · Neutral 30% · Bear 10%
- 1-year price estimates — P10: $3 / P50: $6 / P90: $9
- Prime Medicine's focus on breakthrough technology in gene editing and its ability to secure significant funding rounds position it for strong potential returns within the near term. Analyst targets suggest substantial…
5-Year Outlook
- Bull 70% · Neutral 20% · Bear 10%
- 5-year price estimates — P10: $3 / P50: $15 / P90: $25
SWOT Highlights
- Strength: Innovative gene-editing technology
- Strength: Strong leadership and collaborations
- Risk: Currently unprofitable
- Risk: Dependent on successful clinical trials
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
6 Wall Street analysts rate PRME a BUY with a mean price target of $7.56.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
PRME forecast details · PRME sentiment details · PRME insider activity
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.